ORNBV Orion Oyj Class B

Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

ORION CORPORATION

STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS

22 August 2023 at 14.00 EEST             

        

Change in Orion Group Executive Management Board as of February 1st, 2024Julia Macharey appointed Senior Vice President, People & Culture

Ms. Julia Macharey has been appointed Senior Vice President of Orion Group’s new People & Culture group-level function and member of the Executive Management Board of Orion Group as of February 1st 2024. She will report to President & CEO Liisa Hurme. She currently holds the position of Senior Vice President, Human Resources and Operational Development at Valmet and is a member of the Valmet Executive Team. Julia Macharey holds a Master of Science degree in Economics and a Bachelor of Arts degree.

“With this appointment, I wanted to support the implementation of our global growth strategy and to strengthen the building of Orion's corporate culture. Based on her previous experience and track record, Julia Macharey will bring both global organizational and business perspective to Orion," says Orion’s President & CEO Liisa Hurme.

“I am very excited about the opportunity of joining a team of world-class experts who endeavor to improve well-being through life-saving and life-improving medicines and treatments. Orion’s people-oriented culture based on working together to create high-quality products is only one of the many reasons why I am looking forward to supporting Orion on its growth path,” says Julia Macharey about the appointment.

The new People & Culture function will focus on developing Orion’s professionals, capabilities and company culture and supporting growth, and Human Resources will be at the heart of this new group-level function as of February 1st.

“Orion’s organisation has seen significant geographical expansion in recent years, and we want to continue developing our people and culture in a global and systematic way. I am excited about the new opportunities in this and I warmly welcome Julia to Orion and to our management team,” says Liisa Hurme.

ANNEX: CV of Julia Macharey



Julia Macharey

Born 1977

Finnish citizen



Education:

Master of Science in Economics, University of Jyväskylä, 2000

Bachelor of Arts (Intercultural Communication), University of Jyväskylä, 1999



Career:

Valmet

2019–              Senior Vice President, Human Resources and Operational Development

2014–2019        Senior Vice President, Human Resources



Metso Corporation, Metso Paper

2012–2013        Senior Vice President, Human Resources of Metso Pulp, Paper and Power segment



Pöyry Plc        

2007–2012        Vice President, Human Resources of Industry Business Group





Nokia Corporation

2006–2007        Senior Manager, Business HR of Manufacturing Solutions

2004–2006        Senior Manager, Business HR of Sourcing and Procurement

SCA Hygiene Products Ltd and GmbH

2000–2004        Human Resources Manager and various HR management responsibilities

Attachment:

  •  (image)

Orion Corporation

Liisa Hurme



President and CEO
    Olli Huotari



SVP, Corporate Functions
 

                                                

Contact person:

Liisa Hurme, President and CEO

tel. +358 50 966 2874,

Contact person for the media:

Terhi Ormio, VP, Communications

tel. + 358 50 966 4646,

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 

Attachment



EN
22/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion publishes Interim Report for January–March 2026 and holds a webc...

Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026 ORION CORPORATION PRESS RELEASE 10 APRIL 2026 at 9.00 EEST         Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026        Orion will publish Interim Report for January–March 2026 on Thursday, 23 April 2026 at approximately 12.00 noon EEST. The release and related presentation material will be available on the company’s website at  after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media representatives...

 PRESS RELEASE

Orion julkaisee osavuosikatsauksen 1–3/2026 ja järjestää verkkolähetyk...

Orion julkaisee osavuosikatsauksen 1–3/2026 ja järjestää verkkolähetyksen 23.4.2026 ORION OYJ        LEHDISTÖTIEDOTE        10.4.2026 KLO 9.00         Orion julkaisee osavuosikatsauksen 1–3/2026 ja järjestää verkkolähetyksen 23.4.2026 Orion julkaisee osavuosikatsauksen 1–3/2026 torstaina 23.4.2026 noin klo 12.00. Tiedote ja siihen liittyvä esitysmateriaali ovat julkistuksen jälkeen saatavilla yhtiön verkkosivuilla osoitteessa . Verkkolähetys ja puhelinkonferenssi Englanninkielinen verkkolähetys sekä puhelinkonferenssi analyytikoille, sijoittajille ja toimittajille järjestetään torstai...

 PRESS RELEASE

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vin...

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS1 APRIL 2026 at 16.00 EEST         Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines Orion Corporation (“Orion”) has appointed Berkeley Vincent as Executive Vice President, Innovative Medicines and a member of the Orion Executive Team as of 8 April 2026. The appointment is part of a leadership struc...

 PRESS RELEASE

Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincen...

Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincent nimitetty Innovative Medicines -yksikön johtajaksi ORION OYJ        PÖRSSITIEDOTE – MUUTOKSET HALLITUS/JOHTO/TILINTARKASTUS1.4.2026 KLO 16.00         Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincent nimitetty Innovative Medicines -yksikön johtajaksi Orion-konsernin Innovative Medicines -yksikön johtajaksi ja johtoryhmän jäseneksi on nimitetty 8.4.2026 lukien Berkeley Vincent. Nimitys liittyy organisaation johtamisrakenteen uudistukseen, jossa aiemmin yhdistetty Research & Develo...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS31 March 2026 at 18:00 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch